Braidwell LP Reduces Stake in Dianthus Therapeutics, Inc. $DNTH

Key Points

• Braidwell LP significantly reduced its stake in Dianthus Therapeutics by 68.9%, selling 831,234 shares and now holding 375,355 shares worth approximately $6.81 million.
• Dianthus Therapeutics' share price has dropped by 5.0%, with current trading at $23.57, amid a volatile market and disappointing quarterly earnings results.
• Several institutional investors increased their holdings in Dianthus Therapeutics during the previous quarter, pointing to continued interest from large financial entities in the biotechnology sector.

Braidwell LP lessened its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 68.9% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 375,355 shares of the company's stock after selling 831,234 shares during the quarter. Braidwell LP owned 1.17% of Dianthus Therapeutics worth $6,809,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Millennium Management LLC boosted its position in Dianthus Therapeutics by 160.2% in the fourth quarter. Millennium Management LLC now owns 90,436 shares of the company's stock valued at $1,972,000 after buying an additional 55,682 shares in the last quarter. Moody Aldrich Partners LLC acquired a new stake in Dianthus Therapeutics in the first quarter valued at approximately $1,349,000. Northern Trust Corp boosted its position in Dianthus Therapeutics by 21.2% in the fourth quarter. Northern Trust Corp now owns 245,523 shares of the company's stock valued at $5,352,000 after buying an additional 42,923 shares in the last quarter. Walleye Capital LLC boosted its position in Dianthus Therapeutics by 29.0% in the first quarter. Walleye Capital LLC now owns 106,931 shares of the company's stock valued at $1,940,000 after buying an additional 24,041 shares in the last quarter. Finally, Vestal Point Capital LP boosted its position in Dianthus Therapeutics by 172.2% in the fourth quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company's stock valued at $23,435,000 after buying an additional 680,000 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company's stock.

Analyst Ratings Changes

DNTH has been the topic of a number of research analyst reports. HC Wainwright restated a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research report on Tuesday, May 13th. Robert W. Baird cut their target price on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 13th. William Blair initiated coverage on shares of Dianthus Therapeutics in a research report on Wednesday, July 2nd. They issued an "outperform" rating on the stock. Finally, Wedbush lifted their price target on shares of Dianthus Therapeutics from $34.00 to $42.00 and gave the stock an "outperform" rating in a report on Thursday, August 21st. Seven equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $54.00.

Dianthus Therapeutics Price Performance

Shares of NASDAQ:DNTH traded up $0.40 during midday trading on Thursday, hitting $24.66. 348,965 shares of the company's stock were exchanged, compared to its average volume of 324,647. The stock has a 50 day moving average price of $20.96 and a 200-day moving average price of $20.06. The company has a market cap of $793.81 million, a PE ratio of -7.59 and a beta of 1.46. Dianthus Therapeutics, Inc. has a 12 month low of $13.36 and a 12 month high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%.The firm had revenue of $0.19 million for the quarter, compared to analysts' expectations of $0.87 million. On average, analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.